The prevention of colitis by E prostanoid receptor 4 agonist through enhancement of epithelium survival and regeneration

被引:74
作者
Jiang, Guang-Liang
Nieves, Amelia
Im, Wha Bin
Old, David W.
Dinh, Danny T.
Wheeler, Larry
机构
[1] Allergan Pharmaceut Inc, Herbert Res Ctr, Dept Biol Sci, Irvine, CA 92612 USA
[2] Allergan Pharmaceut Inc, Herbert Res Ctr, Dept Med Chem, Irvine, CA 92612 USA
关键词
D O I
10.1124/jpet.106.111146
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Inflammatory bowel disease (IBD) is often triggered and/or exacerbated by nonsteroidal anti-inflammatory drugs (NSAIDs). Among various prostanoids affected by NSAIDs, prostaglandin E-2 (PGE(2)), in particular, seems to play critical roles in IBD via the EP4 receptor, one of the four PGE(2) receptor subtypes (EP1-4). An EP4 agonist, [[3-[[(1R, 2S, 3R)-3-hydroxy-2-[(1E,3S)-3-hydroxy-4-[3-(methoxymethyl)phenyl]-1-butenyl]-5-oxocyclopentyl]thio]propyl] thio]-acetic acid, C22H30O6S2 (ONO-AE1-329), for example, when topically applied, has been reported to ameliorate typical colitis symptoms by suppressing the production of cytotoxic cytokines in the dextran sodium sulfate (DSS)-induced colitis model. EP4 agonists are also known, however, for their ability to protect epithelial cells from apoptosis in vitro, which may contribute to the protection of mucosal barrier functions. To investigate this potential application, we have tested another EP4-selective agonist in the DSS-indomethacin mouse colitis model. 7-[2-(3-Hydroxy-4-phenyl-but-1-enyl)-6-oxo-piperidin-1-yl]-heptanoic acid methyl ester, C23H33NO4 (AGN205203), an analog from the 8-azapiperidinone series of EP4 agonists, is metabolically and chemically more stable than the ONO agonist, because of its lack of oxidizable sulfur atoms in the alpha-chain and of 11-OH group, a potential source of beta-elimination reaction. Treatment of mice subcutaneously with AGN205203 at 3 mg/kg/day minimized colitis symptoms, such as weight loss, diarrhea, and colonic bleeding. Further histological examination of colons revealed healthy surface columnar epithelial cells free of erosion and ulceration compared with those without the drug treatment. At cellular level, the drug treatment decreased colon epithelial apoptosis, prevented goblet cell depletion, and promoted epithelial regeneration. AGN205203 may be unique among known EP4 agonists for its metabolic and chemical stability, and it is amenable to systemic applications for the prevention and recovery of IBD.
引用
收藏
页码:22 / 28
页数:7
相关论文
共 37 条
[11]   Pharmacology and signaling of prostaglandin receptors: Multiple roles in inflammation and immune modulation [J].
Hata, AN ;
Breyer, RM .
PHARMACOLOGY & THERAPEUTICS, 2004, 103 (02) :147-166
[12]   Prostaglandin E2 protects gastric mucosal cells from apoptosis via EP2 and EP4 receptor activation [J].
Hoshino, T ;
Tsutsumi, S ;
Tomisato, W ;
Hwang, HJ ;
Tsuchiya, T ;
Mizushima, T .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2003, 278 (15) :12752-12758
[13]   State of the art: IBD therapy and clinical trials in IBD [J].
Isaacs, KL ;
Lewis, JD ;
Sandborn, WJ ;
Sands, BE ;
Targan, SR .
INFLAMMATORY BOWEL DISEASES, 2005, 11 :S3-S12
[14]   Prostaglandins and activation of AC/cAMP prevents anoikis in IEC-18 [J].
Joseph, RR ;
Yazer, E ;
Hanakawa, Y ;
Stadnyk, AW .
APOPTOSIS, 2005, 10 (06) :1221-1233
[15]  
Kabashima K, 2002, J CLIN INVEST, V109, P883, DOI 10.1172/JCI200214459
[16]   Histological analysis of murine colitis induced by dextran sulfate sodium of different molecular weights [J].
Kitajima, S ;
Takuma, S ;
Morimoto, M .
EXPERIMENTAL ANIMALS, 2000, 49 (01) :9-15
[17]   Collagen-binding integrin α1β1 regulates intestinal inflammation in experimental colitis [J].
Krieglstein, CF ;
Cerwinka, WH ;
Sprague, AG ;
Laroux, FS ;
Grisham, MB ;
Koteliansky, VE ;
Senninger, N ;
Granger, DN ;
de Fougerolles, AR .
JOURNAL OF CLINICAL INVESTIGATION, 2002, 110 (12) :1773-1782
[18]  
Lim Wee-Chian, 2004, Rev Gastroenterol Disord, V4, P66
[19]   Clinical epidemiology of inflammatory bowel disease: Incidence, prevalence, and environmental influences [J].
Loftus, EV .
GASTROENTEROLOGY, 2004, 126 (06) :1504-1517
[20]   Systematic review: short-term adverse effects of 5-aminosalicylic acid agents in the treatment of ulcerative colitis [J].
Loftus, EV ;
Kane, SV ;
Bjorkman, D .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2004, 19 (02) :179-189